Douglas A. Jabs, MD, Delivers Jackson Memorial Lecture at the American Academy of Ophthalmology Annual Meeting
Dr. Jabs has been awarded the Jackson Memorial Lecture by the American Academy of Ophthalmology. He will discuss research developments in cytomegalovirus retinitis in people with AIDS.
Douglas A. Jabs, MD, MBA, Professor and Chair of the Department of Ophthalmology, CEO of the Faculty Practice Associates, and Dean for Clinical Affairs at The Mount Sinai Medical Center, has been selected to deliver the prestigious Jackson Memorial Lecture at the 2010 Annual Meeting of the American Academy of Ophthalmology. The lecture will be published in the November issue of the American Journal of Ophthalmology.
In a presentation titled “Cytomegalovirus Retinitis and AIDS: Bench to Bedside,” Dr. Jabs will discuss clinical and molecular research over the last 20 years on cytomegalovirus (CMV) retinitis, a viral inflammation in the retina, in people with AIDS. He will provide a synthesis of what researchers have learned about the pathogenesis of CMV retinitis and its interaction with HIV, reviewing several major epidemiologic studies.
“The data we have collected over the years has helped us better understand the behavior of cytomegalovirus retinitis at the molecular level, and bring that knowledge to the clinical setting,” said Dr. Jabs. “Understanding the virology of this opportunistic infection and how it interacts with HIV will help us develop optimal paradigms for treating it.”
A leading expert in inflammatory disorders of the eye, Dr. Jabs has co-authored more than 200 publications and 40 book chapters. His primary research interests include the treatment of uveitis, or the inflammation of the uvea in the eye, and ocular complications associated with AIDS and autoimmune diseases. He is chair of the Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, which is conducting clinical trials of treatments for severe uveitis, and the Studies of Ocular Complications of AIDS (SOCA) Research Group, which has conducted several randomized, multicenter, controlled trials on CMV retinitis and a long-term cohort study of the ocular complications of AIDS in the current era.
“We are proud that the American Academy of Ophthalmology has recognized Dr. Jabs and his work in CMV retinitis and AIDS,” said Dennis Charney, M.D., Anne and Joel Ehrenkranz Dean of Mount Sinai School of Medicine and Executive Vice President for Academic Affairs at The Mount Sinai Medical Center. “His commitment to ground-breaking translational research in ophthalmology makes him a true asset to Mount Sinai and to the field.”
Prior to joining Mount Sinai, Dr. Jabs was the Alan C. Woods Professor of Ophthalmology and Professor of Medicine at The Johns Hopkins University School of Medicine, Professor of Epidemiology at The Johns Hopkins University Bloomberg School of Public Health, and the Director of the Division of Ocular Immunology at The Wilmer Eye Institute. After receiving his medical degree from The Johns Hopkins University School of Medicine he completed an internship in internal medicine at Cornell Medical Center/New York Hospital, a residency in internal medicine at The Johns Hopkins Hospital, a residency in ophthalmology at The Wilmer Eye Institute, and a fellowship in rheumatology at The Johns Hopkins Medical Institutions. In 1984, he joined the faculty at The Johns Hopkins University School of Medicine, where he remained until joining Mount Sinai in 2007.
Dr. Jabs has received several awards for his research and clinical accomplishments, including the Research to Prevent Blindness Olga Keith Wiess Scholar Award, the Research to Prevent Blindness Lew R. Wasserman Merit Award, the Research to Prevent Blindness Senior Scientific Investigator, the American Academy of Ophthalmology Achievement Award and Senior Achievement Award, and the Ethel Baxter Award for Excellence in Research from the Sjögren's Syndrome Foundation.
The Jackson Memorial Lecture is named for Dr. Edward Jackson, who helped establish the modern ophthalmology field. He helped create the American Board of Ophthalmology and developed its first board examination. He also helped pave the way for future medical conference both within Ophthalmology and in other fields by advocating for instructional courses at the annual meeting. Previous Jackson Memorial Lecturers include: Harry A. Quigley, MD, who spoke about Angle Closure Glaucoma; Frederick L. Ferris III, MD, whose lecture focused on the benefit of clinical trials beyond evaluating treatment effect; and Edwin M. Stone, MD, PhD, who discussed the role of genetic testing in finding a cure for Leber Congenital Amaurosis.
“I am honored and humbled to follow in the footsteps of the long line of research pioneers in ophthalmology who have delivered the Jackson Memorial Lecture,” said Dr. Jabs. “I hope my presentation will help stimulate discussion of improving clinical outcomes in patients with AIDS and CMV retinitis.”
About The Mount Sinai Medical Center
The Mount Sinai Medical Center encompasses both The Mount Sinai Hospital and Mount Sinai School of Medicine. Established in 1968, Mount Sinai School of Medicine is one of few medical schools embedded in a hospital in the United States. It has more than 3,400 faculty in 32 departments and 15 institutes, and ranks among the top 20 medical schools both in National Institute of Health funding and by U.S. News & World Report. The school received the 2009 Spencer Foreman Award for Outstanding Community Service from the Association of American Medical Colleges.
The Mount Sinai Hospital, founded in 1852, is a 1,171-bed tertiary- and quaternary-care teaching facility and one of the nation's oldest, largest and most-respected voluntary hospitals. U.S. News & World Report consistently ranks The Mount Sinai Hospital among the nation's best hospitals based on reputation, patient safety, and other patient-care factors. Nearly 60,000 people were treated at Mount Sinai as inpatients last year, and approximately 530,000 outpatient visits took place.
For more information, visit www.mountsinai.org. Follow us on Twitter @mountsinainyc.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across seven hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Instagram, LinkedIn, X, and YouTube.
Researchers Identify Potential Target for Treatment Among Patients With Type 2 Diabetes
Aug 04, 2022 View All Press Releases
Mount Sinai Researcher Receives Prestigious International Award
Jul 06, 2022 View All Press Releases
Combination of Chemo and Immunotherapy Is Shown to Work Against Metastatic Bladder Cancer
May 15, 2020 View All Press Releases